Back to results
US 2005/0232933 A1Published application
CMV-IE1 peptides and method of use
OwnerJohn Zaia, Ghislaine Gallez-Hawkinsinventors
Life of this patent
Estimating the term…
Abstract
IE1 peptide antigens that are recognized by and stimulate production of CMV-specific cytotoxic T lymphocytes are useful for vaccines, in the form of peptides, DNA vaccines or cellular vaccines, and also for diagnostic methods.
Claims11
A CMV peptide composition which comprises a peptide selected from the group consisting of SEQ ID NOS:
- 1, 2 and 3.
A peptide selected from the group consisting of SEQ ID NOS:
- 1, 2 and 3.
A DNA vaccine that encodes a peptide selected from the group consisting of SEQ ID NOS:
- 1, 2 and 3.
Dependencies are inferred from the claim text.